So what have the benefits been? Has there been a positive outcome for patients?
MIMS (a journal working within the Conventional Medical Establishment) has reported that “ADHD medication use in UK women increases more that 20-fold in 13 years”. The article says that, according to a new study, the use of ADHD drugs among women aged 25 years or older increased by more than 20-fold between 2010 and 2023.
So what good has this increased ‘medication’ done for ADHD sufferers? I decided to ask my AI programme “How much has ADHD increased in the last 13 years in the UK? This is the answer I received.
“ADHD diagnosis rates in the UK have significantly increased, with a seven-fold rise in adult ADHD prescriptions over the last decade. As of 2024/25, approximately 1.6% of males and 0.9% of females had a recorded ADHD diagnosis, up from 0.7% and 0.2% respectively in 2016/17”
The most important feature of an effective medical system should be it’s ability to produce a positive outcome in the health of patients.
When pharmaceutical drug are taken to address an illness, and the result is that diagnosis rates increase “significantly”, the only ‘positive outcome’ it might suggest would be an increase in pharmaceutical profitability!
Plus, maybe, for anyone willing to consider such a possibility, it points to yet another failure of pharmaceutical drugs to produce a ‘positive outcome’ for patients.
